Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

J Dermatolog Treat. 2010 May;21(3):185-92. doi: 10.3109/09546630903493311.

Abstract

We evaluated in this study the efficacy and safety of an alternate regimen using clobetasol propionate 0.05% shampoo (CP shampoo) for long-term control of scalp psoriasis. Patients with moderate scalp psoriasis (Global Severity Score [GSS] of 3 on a 0-5 scale) first received CP shampoo once daily for 4 weeks. Patients with a GSS <or= 2 were then randomized into the maintenance phase, receiving CP shampoo or vehicle twice weekly. When relapse (GSS > 2) occurred, patients received the 4-week daily CP shampoo treatment. Patients who had a GSS <or= 2 afterwards reinitiated the twice-weekly maintenance according to the original randomization scheme. Among the 168 patients enrolled, 141 (83.9%) had a GSS <or= 2 after the initial phase. The median time to first relapse was 141 days with CP shampoo, almost 4 months later than with vehicle (30.5 days;p < 0.0001). After 6 months, the percentage of patients who had no relapse was significantly higher with CP shampoo (40.3%) than with vehicle (11.6%;p < 0.001). CP shampoo was also safe during the 7-month study period, without leading to more cases of skin atrophy, telangiectasia, hypothalamic-pituitary-adrenal (HPA) axis suppression or adverse events compared to vehicle. The alternate treatment regimen with CP shampoo is efficacious and safe for long-term management of moderate scalp psoriasis.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Clobetasol / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug-Related Side Effects and Adverse Reactions
  • Female
  • Follow-Up Studies
  • Hair Preparations
  • Humans
  • Long-Term Care
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Probability
  • Psoriasis / diagnosis*
  • Psoriasis / drug therapy*
  • Reference Values
  • Risk Assessment
  • Scalp Dermatoses / diagnosis*
  • Scalp Dermatoses / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Hair Preparations
  • Clobetasol